140 related articles for article (PubMed ID: 37732232)
1. Use of SGLT2i and ARNi in patients with atrial fibrillation and heart failure in 2021-2022: an analysis of real-world data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
medRxiv; 2023 Sep; ():. PubMed ID: 37732232
[TBL] [Abstract][Full Text] [Related]
2. Use of Sodium-Glucose Cotransporter-2 Inhibitors and Angiotensin Receptor-Neprilysin Inhibitors in Patients With Atrial Fibrillation and Heart Failure From 2021 to 2022: An Analysis of Real-World Data.
Alonso A; Morris AA; Naimi AI; Alam AB; Li L; Subramanya V; Chen LY; Lutsey PL
J Am Heart Assoc; 2024 Mar; 13(6):e032783. PubMed ID: 38456406
[TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First Strategy.
Lee WC; Chang WT; Hong CS; Liao CT; Huang PS; Huang SC; Lin CH; Chiang CY; Chen ZC; Shih JY
Front Biosci (Landmark Ed); 2023 Apr; 28(4):81. PubMed ID: 37114551
[TBL] [Abstract][Full Text] [Related]
4. The cardiovascular effects of SGLT2 inhibitors, RAS inhibitors, and ARN inhibitors in heart failure.
Ji PJ; Zhang ZY; Yan Q; Cao HL; Zhao YJ; Yang B; Li J
ESC Heart Fail; 2023 Apr; 10(2):1314-1325. PubMed ID: 36722326
[TBL] [Abstract][Full Text] [Related]
5. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction.
Sartipy U; Dahlström U; Fu M; Lund LH
JACC Heart Fail; 2017 Aug; 5(8):565-574. PubMed ID: 28711451
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of heart failure phenotypes and current use of therapies in primary care: results from a nationwide study.
Jensen J; Poulsen MK; Petersen PW; Gerdes B; Rossing K; Schou M
ESC Heart Fail; 2023 Jun; 10(3):1745-1756. PubMed ID: 36852608
[TBL] [Abstract][Full Text] [Related]
7. [Contemporary epidemiology and treatment of hospitalized heart failure patients in real clinical practice in China].
Wang H; Li YY; Chai K; Zhang W; Li XL; Dong YG; Zhou JM; Huo Y; Yang JF
Zhonghua Xin Xue Guan Bing Za Zhi; 2019 Nov; 47(11):865-874. PubMed ID: 31744275
[No Abstract] [Full Text] [Related]
8. Prescribing trends of SGLT2 inhibitors among HFrEF and HFpEF patients with and without T2DM, 2013-2021.
Gonzalez J; Dave CV
BMC Cardiovasc Disord; 2024 May; 24(1):285. PubMed ID: 38816795
[TBL] [Abstract][Full Text] [Related]
9. Combining sodium-glucose cotransporter 2 inhibitors and angiotensin receptor-neprilysin inhibitors in heart failure patients with reduced ejection fraction and diabetes mellitus: A multi-institutional study.
Hsiao FC; Lin CP; Tung YC; Chang PC; McMurray JJV; Chu PH
Int J Cardiol; 2021 May; 330():91-97. PubMed ID: 33587940
[TBL] [Abstract][Full Text] [Related]
10. Thromboembolisms in atrial fibrillation and heart failure patients with a preserved ejection fraction (HFpEF) compared to those with a reduced ejection fraction (HFrEF).
Sobue Y; Watanabe E; Lip GYH; Koshikawa M; Ichikawa T; Kawai M; Harada M; Inamasu J; Ozaki Y
Heart Vessels; 2018 Apr; 33(4):403-412. PubMed ID: 29067492
[TBL] [Abstract][Full Text] [Related]
11. SGLT2i versus ARNI in heart failure with reduced ejection fraction: a systematic review and meta-analysis.
Yan Y; Liu B; Du J; Wang J; Jing X; Liu Y; Deng S; Du J; She Q
ESC Heart Fail; 2021 Jun; 8(3):2210-2219. PubMed ID: 33749159
[TBL] [Abstract][Full Text] [Related]
12. Atrial fibrillation and risk of progressive heart failure in patients with preserved ejection fraction heart failure.
Gierula J; Cole CA; Drozd M; Lowry JE; Straw S; Slater TA; Paton MF; Byrom RJ; Garland E; Halliday G; Winsor S; Lyall GK; Birch K; McGinlay M; Sunley E; Grant PJ; Wessels DH; Ketiar EM; Witte KK; Cubbon RM; Kearney MT
ESC Heart Fail; 2022 Oct; 9(5):3254-3263. PubMed ID: 35790085
[TBL] [Abstract][Full Text] [Related]
13. Heart failure progression and mortality in atrial fibrillation patients with preserved or reduced left ventricular ejection fraction.
Slee A; Saad M; Saksena S
J Interv Card Electrophysiol; 2019 Sep; 55(3):325-331. PubMed ID: 30887281
[TBL] [Abstract][Full Text] [Related]
14. Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
Chandra A; Vaduganathan M; Lewis EF; Claggett BL; Rizkala AR; Wang W; Lefkowitz MP; Shi VC; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV; Solomon SD;
JACC Heart Fail; 2019 Oct; 7(10):862-874. PubMed ID: 31302043
[TBL] [Abstract][Full Text] [Related]
15. Pharmacotherapies in Heart Failure With Preserved Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Sreenivasan J; Malik A; Khan MS; Lloji A; Hooda U; Aronow WS; Lanier GM; Pan S; Greene SJ; Murad MH; Michos ED; Cooper HA; Gass A; Gupta R; Desai NR; Mentz RJ; Frishman WH; Panza JA
Cardiol Rev; 2024 Mar-Apr 01; 32(2):114-123. PubMed ID: 36576372
[TBL] [Abstract][Full Text] [Related]
16. Atrial fibrillation and risk of incident heart failure with reduced versus preserved ejection fraction.
Nicoli CD; O'Neal WT; Levitan EB; Singleton MJ; Judd SE; Howard G; Safford MM; Soliman EZ
Heart; 2022 Mar; 108(5):353-359. PubMed ID: 34031160
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and Prognostic Implication of Atrial Fibrillation in Heart Failure Subtypes: Systematic Review and Meta-Analysis.
Mundisugih J; Franke KB; Tully PJ; Munawar DA; Kumar S; Mahajan R
Heart Lung Circ; 2023 Jun; 32(6):666-677. PubMed ID: 37003940
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of ARNI and SGLT2 inhibitors in diabetic patients with heart failure with reduced ejection fraction.
Kim HM; Hwang IC; Choi W; Yoon YE; Cho GY
Sci Rep; 2021 Nov; 11(1):22342. PubMed ID: 34785723
[TBL] [Abstract][Full Text] [Related]
19. Left atrial volume and left ventricular mass indices in heart failure with preserved and reduced ejection fraction.
Gehlken C; Screever EM; Suthahar N; van der Meer P; Westenbrink BD; Coster JE; Van Veldhuisen DJ; de Boer RA; Meijers WC
ESC Heart Fail; 2021 Aug; 8(4):2458-2466. PubMed ID: 34085774
[TBL] [Abstract][Full Text] [Related]
20. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
